Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single-agent selinexor, an oral selective inhibitor of nuclear export, in patients with relapsed or refractory DLBCL who had n...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Lancet. Haematology 2020-07, Vol.7 (7), p.e511-e522
Hauptverfasser:	Kalakonda, Nagesh, Maerevoet, Marie, Cavallo, Federica, Follows, George, Goy, Andre, Vermaat, Joost S P, Casasnovas, Olivier, Hamad, Nada, Zijlstra, Josée M, Bakhshi, Sameer, Bouabdallah, Reda, Choquet, Sylvain, Gurion, Ronit, Hill, Brian, Jaeger, Ulrich, Sancho, Juan Manuel, Schuster, Michael, Thieblemont, Catherine, De la Cruz, Fátima, Egyed, Miklos, Mishra, Sourav, Offner, Fritz, Vassilakopoulos, Theodoros P, Warzocha, Krzysztof, McCarthy, Daniel, Ma, Xiwen, Corona, Kelly, Saint-Martin, Jean-Richard, Chang, Hua, Landesman, Yosef, Joshi, Anita, Wang, Hongwei, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Van Den Neste, Eric, Canales, Miguel A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Disease-Free Survival Exportin 1 Protein Female Humans Hydrazines - therapeutic use Karyopherins - antagonists & inhibitors Lymphoma, Large B-Cell, Diffuse - drug therapy Male Middle Aged Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors Triazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!